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Abstract
Background The use of zoledronic acid (ZOL) has
recently been shown to signiﬁcantly reduce the risk of new
skeletal-related events (SREs) in renal cell carcinoma
(RCC) patients with bone metastases. The present explor-
atory study assessed the cost-effectiveness of ZOL in this
population, adopting a French, German, and United King-
dom (UK) government payer perspective.
Materials and methods This cost-effectiveness model
was based on a post hoc retrospective analysis of a subset
of patients with RCC who were included in a larger ran-
domized clinical trial of patients with bone metastases
secondary to a variety of cancers. In the trial, patients were
randomized to receive ZOL (n = 27) or placebo (n = 19)
with concomitant antineoplastic therapy every 3 weeks for
9 months (core study) plus 12 months during a study
extension. Since the trial did not collect costs or data on the
quality-adjusted life years (QALYs) of the patients, these
outcomes had to be assumed via modeling exercises. The
costs of SREs were estimated using hospital DRG tariffs.
These estimates were supplemented with literature-based
costs where possible. Drug, administration, and supply
costs were obtained from published and internet sources.
Consistent with similar economic analyses, patients were
assumed to experience quality of life decrements lasting
1 month for each SRE. Uncertainty surrounding outcomes
was addressed via multivariate sensitivity analyses.
Results Patients receiving ZOL experienced 1.07 fewer
SREsthanpatientsonplacebo.PatientsonZOLexperienced
a gain in discounted QALYs of approximately 0.1563 in
France and Germany and 0.1575 in the UK. Discounted
SRE-relatedcostsweresubstantiallyloweramongZOLthan
placebopatients(-€4,196inFrance,-€3,880inGermany,
and -€ 3,355 in the UK). After taking intoconsideration the
drugtherapycosts,ZOLsaved €1,358,€1,223,and€719in
France, Germany, and the UK, respectively. In the multi-
variate sensitivityanalyses,therapy with ZOLsavedcostsin
67–77% of simulations, depending on the country. The cost
per QALY gained for ZOL versus placebo was below €
30,000 per QALY gained threshold in approximately
93–94% of multivariate sensitivity analyses simulations.
Conclusions The present analysis suggests that ZOL
saves costs and increases QALYs compared to placebo in
French, German, and UK RCC patients with bone metas-
tases. Additional prospective research may be needed to
conﬁrm these results in a larger sample of patients.
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Introduction
Patients with advanced renal cell carcinoma (RCC) are at a
high risk for developing skeletal-related events (SREs)
[1, 2]. Approximately 80% of RCC patients with bone
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ence a long-bone fracture, and 30% require orthopedic
surgery or develop hypercalcemia [1]. Health status,
quality of life, and survival are negatively impacted by
these SREs [3, 4]. In addition, the cost of managing SREs
due to cancer is substantial [5, 6].
Bisphosphonates are increasingly used to prevent the
burden of SREs in patients with bone metastases [7].
Zoledronic acid (ZOL) is the only bisphosphonate proven
to safely and effectively reduce SREs in RCC patients with
bone metastases. Speciﬁcally, ZOL was investigated in a
randomized, double-blind, placebo-controlled, Phase III
trial in patients with bone metastases secondary to solid
tumors other than breast or prostate cancer, including non-
small cell lung cancer, RCC, and bladder cancer [8, 9]. The
incidence of SREs was particularly high among the sub-
group of patients with RCC (which included 27 patients
receiving ZOL 4 mg and 19 patients receiving placebo,
both administered as a 15-min infusion) [10], demonstrat-
ing the aggressive nature of bone metastases from RCC. A
post hoc analysis by Lipton et al. [10] revealed that ZOL
was efﬁcacious in patients with RCC. During the 9-month
trial [10], ZOL (a) signiﬁcantly reduced the proportion of
patients with an SRE by 50% (37% versus 74% with pla-
cebo, P B 0.015); (b) consistently reduced the proportion
of patients with each type of SRE; (c) signiﬁcantly pro-
longed time to ﬁrst SRE (median not reached at 270 days
versus 72 days for placebo, P B 0.006); (d) signiﬁcantly
delayed the time to ﬁrst pathological fracture (median not
reached at 9 months versus 168 days for placebo); (e)
signiﬁcantly reduced the skeletal morbidity rate by 21%
(2.68 versus 3.38 events per year for placebo; P B 0.014);
and (f) signiﬁcantly reduced the risk of SRE (risk ratio,
0.394; 95% conﬁdence interval, 0.193–0.806; P B 0.008)
in an Andersen-Gill multiple event analysis (which incor-
porated the incidence and timing of all of the SREs
throughout the study and accounts for inter- and intrapa-
tient variations in event rate). In this trial, ZOL was well
tolerated by RCC patients. The clinical adverse event (AE)
proﬁle in patients receiving ZOL was similar to placebo.
Compared to placebo, AEs with greater incidences in the
ZOL treatment arm included nausea, anemia, pyrexia,
emesis, and dyspnea. The renal safety proﬁle of ZOL was
comparable to placebo [10]. In contrast to the available
data regarding ZOL, there is no evidence regarding the
effects of other bisphosphonates (e.g., pamidronate) in
patients with RCC.
Given the substantial burden of SREs and the high efﬁ-
cacy of ZOL in the RCC patient population, we hypothe-
sized that the use of ZOL in this setting would be highly
cost-effective. This hypothesis was based on the previous
analyses showing that ZOL is cost-effective in solid tumors
other than RCC, such as breast [11], prostate [12], and lung
[13]. Therefore, the purpose of the present analysis was to
estimate the cost-effectiveness of ZOL versus placebo in
RCC patients with bone metastases. The analysis was
conducted from a government payer perspective in the three
most populous European Union (EU) countries, namely,
France, Germany, and the United Kingdom (UK), which
account for approximately two-ﬁfths of the nearly 500
million European Union populations.
Materials and methods
Study design
An economic model was conducted to estimate the cost-
effectiveness of ZOL versus placebo in RCC patients with
bone metastases. The most universally accepted, and, in
some countries, mandated method to assess value is the
‘‘cost utility analysis’’, a form of cost-effectiveness anal-
ysis in which health effects are measured in terms of
quality-adjusted life years (QALYs) gained. A QALY is a
measure that incorporates both the quantity of life (how
long a therapy improves survival) and the quality of life
(how desirable the additional survival is). Measuring the
desirability of a health state is accomplished via the use of
utility, which is a quantitative expression of an individual’s
preference for a particular health state.
Therefore, in the present analysis, the main outcome
measure was the incremental cost-utility ratio (ICUR) of
using ZOL as opposed to placebo (i.e., no bisphosphonate),
which calculates the additional costs (over placebo) asso-
ciated with the use of ZOL to achieve a gain of one
additional QALY (over placebo).
The analysis included direct medical costs associated
with ZOL drug costs, drug administration and supplies, and
the direct costs of SREs. It excluded indirect (i.e., pro-
ductivity) costs incurred (or avoided) by the patients, as the
median age of the patients in the trial was approximately
65 years and it was assumed that the majority of them
would be out of the labor force due to their age and/or the
advance nature of their cancer.
The analysis was based on patient-level data (obtained
from the manufacturer of ZOL, Novartis Pharmaceutical
Corporation, Florham Park, NJ, USA) from a subset of
RCC patients [10] enrolled in a randomized, placebo-
controlled clinical trial of ZOL in patients with bone
metastases from lung or other solid tumors [8, 9]. In the
trial, patients were randomized to receive ZOL (4 or 8 mg)
or placebo every 3 weeks for 9 months, followed with
another 12 month in an extension study. SREs and AEs
were recorded at each 3-week visit. The analysis was based
on the entire 21 months, i.e., the 12 months extension
study in addition to the core 9 months study.
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123No quality of life or cost outcomes were collected during
the clinical trial. For the purpose of this analysis, these
outcomes were modeled by supplementing the trial data
with information from other sources, as described in a
subsequent section (see ‘‘Quality of Life Inputs’’). Speciﬁ-
cally, for each patient enrolled in the trial, the following
trial information was included: overall survival, occurrence
of each type of SRE (pathological vertebral fracture; path-
ological non-vertebral fracture; spinal cord compression;
radiation therapy; hypercalcemia; surgery to bone), and
total number of infusions of ZOL (or placebo). On the basis
of these data, estimates of the quality-adjusted survival and
SRE-related costs were constructed for each individual by
assigning to each patient experiencing a speciﬁc SRE an
increase in costs (corresponding to the estimated cost of
managing the SRE) and a reduction in quality of life (i.e.,
utility), which was then expressed in QALYs. The time
spent by each patient without an SRE was assumed to be
associated with the estimated utility of an average patient
with advanced RCC with bone metastases but without
SREs, as explained in detailed in the next sections.
Clinical inputs
As reported in Lipton et al. [10], the median overall sur-
vival in these RCC patients showed a trend toward favoring
ZOL (295 days for the 4-mg ZOL group versus 216 days
for the placebo group) but did not achieve statistical sig-
niﬁcance compared with placebo (P = 0.179). The average
duration of survival was 264.16 days in the placebo group
and 330.70 days in the ZOL group. For the purpose of the
analysis, the observed survival of the patients was used
and, therefore, any difference in (mean) survival between
groups was included for analysis.
The number of SREs recorded in each cohort is presented
in Table 1. As reported in Lipton et al. [10], the frequency
of SREs was statistically signiﬁcantly less among patients
receiving ZOL. Speciﬁcally, the percentage of patients who
experienced an SRE was reduced signiﬁcantly for the 4-mg
ZOL group (37%) compared with the placebo group (74%;
P = 0.015) [10]. The annual incidence of skeletal compli-
cations, or skeletal morbidity rate, was reduced from a mean
of 3.38 events per year for patients in the placebo group to
2.68 events per year (P = 0.014) for patients who were
treated with 4 mg of ZOL [10].
Cost inputs
The published literature regarding costs of SREs is limited.
In particular, a search did not identify cost estimates for
Germany or France. Thus, SRE costs were estimated on the
basis of hospital statistics regarding diagnosis-related
groups (DRGs) (GHS in France, G-DRG in Germany, and
HRG in the UK) (summarized in Table 2 and detailed in
the Appendix).
Given that 34% of vertebral fractures in cancer patients
[14] and 33% in the general population [15] are symp-
tomatic and 7% [14] of fractures in cancer patients and
approximately 8% in the general population [15] are
managed in the hospital, the cost of treating a pathological
vertebral fracture was assumed to be only 7% of the DRG
costs. For example, in France the DRG cost of a hospi-
talized vertebral fracture was € 5,326. Therefore, in the
model, the cost of vertebral fractures was estimated at only
€ 373 (€ 5,326 9 7%).
For each patient receiving ZOL therapy, the total cost of
infusion was estimated by multiplying the number of
infusions received during the trial (9.78 per patient [range:
1–30]) by the estimated cost of an infusion, including drug
costs (obtained from price and/or reference lists) (sum-
marized in Table 2 and detailed in the Appendix). The
costs of labor, material, and supplies were based on a time
and motion study detailing the tasks and resource con-
sumption associated with the use of ZOL [16]. The
Table 1 Number of SREs in ZOL and Placebo groups
ZOL 4 mg (n = 27) Placebo (n = 19)
Number
of SREs
SRE per person
per year
a
Number
of SREs
SRE per person
per year
a
Pathological vertebral fractures 1 0.041 5 0.364
Pathological non-vertebral fractures 3 0.123 9 0.655
Spinal cord compression 1 0.041 3 0.218
Radiation therapy 10 0.409 12 0.873
Surgery to the bone 3 0.123 4 0.291
All SREs 18 0.736 33 1.349
Every counted SRE was followed by 20-day period during which no SRE was counted
No patients experienced hypercalcemia
a SRE/(Average survival in years 9 number of patients)
Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events 577
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various sources (Appendix).
Quality of life inputs
Limited information exists regarding the level of utility
experienced by patients with advanced stage RCC. A search
of Medline identiﬁed only one study reporting on the utility
of patients with metastatic RCC enrolled in a large, inter-
national, randomized Phase III trial of sunitinib (N = 375)
comparedtointerferonalfa(N = 375)asﬁrst-line treatment
therapy [17]. Health state utilities were measured via the
EuroQol Group’s self-reported health status measure (EQ-
5D), including the population preference-based health state
utility score (EQ-5D Index) and a patient’s overall health
state on a visual analog scale (EQ-VAS). Both the EQ-5D
Index and the EQ-VAS have been shown to be reliable and
valid for assessing health-related quality of life in cancer
patients. At baseline, the EQ-5D Index was 0.76 (standard
deviation [SD] = 0.23) in both groups. The EQ-VAS was
73.80 mm (SD = 18.50 mm) for sunitinib and 71.43 mm
(SD = 19.51 mm) for interferon alfa patients. Thus, for the
purpose of the present analysis, the baseline utility of met-
astatic RCC (without SRE) was assumed to be 0.76.
Consistent with previous economic analyses of bis-
phosphonates in cancer [11, 18], patients experiencing a
SRE were expected to incur a reduction in utility for a
period of 1 month. The reduction in quality of life was
assumed to vary by type of SRE (Table 3), based on the
previous work by Hillner et al. [18]. For example, a patient
with spinal cord compression was assumed to experience a
reduction in quality of life of 80% from the baseline score
of 0.76 for a period of 1 month. The negative impact of
vertebral fractures on utility was assumed to occur only
among those patients who were symptomatic (34%), as
reported in patients with vertebral fractures in another
cancer [14] and in the general population [15].
Analyses
To estimate the ICUR, the economic analysis ﬁrst estimates
the average total cost of treatment with ZOL (CZ) and
placebo (Cp) and average QALYs gained for ZOL (EZ) and
placebo (Ep). Next, the ICUR was calculated with the
following formula:
ICURz p ¼
Cz   Cp
Ez   Ep
ð1Þ
Whether ZOL is cost-effective compared to placebo
depends on whether its ICUR exceeds or remains below
a generally accepted, societal maximum willingness to pay
(WTP) (k). That is, ZOL was considered cost-effective
relative to placebo if:
ICURz p ¼
Cz   Cp
Ez   Ep
 k ð2Þ
For instance, a given therapy can be considered cost-
effective ifitsICURis B€30,000(i.e.,k = €30,000).Ifthe
difference in cost (CZ - Cp) is negative and the difference
inQALY(EZ - Ep)ispositive,thenZOLcanbeconsidered
to be the dominant or preferred option, as it both saves costs
and saves QALYs. Univariate sensitivity analyses on
individual model parameters (using ranges described in
Table 4) were conducted to assess the uncertainty
surrounding the estimate of the cost-effectiveness ratio
(cost per QALY gained). To facilitate comparisons across
various sensitivity analysis scenarios, the ICUR was
mathematically re-arranged linearly into a net monetary
beneﬁt (NMB)framework [19]. TheNMBwas calculatedas
difference in QALYs multiplied by the WTP (k) minus the
difference in cost of therapy. Therefore, with the same
parameter deﬁnitions, the NMB may be deﬁned by:
NMBz p ¼ Ez   Ep

  k   Cz   Cp

ð3Þ
If the NMB is greater than zero, then ZOL is cost-effective
compared to placebo; if equal to zero, the strategies are
equivalent; and less than zero, placebo is more cost-
effective given the maximum WTP (k) for a QALY gained.
The greater the magnitude of the NMB, the larger the
difference in cost-effectiveness will be.
Table 2 Costs of drug, drug administration, and supplies by country
France Germany UK
Drug cost € 270.00 € 254.00 € 218.32
Administration costs € 18.72 € 17.80 € 47.68
Supplies costs € 3.36 € 1.72 € 4.86
Total per infusion € 292.08 € 273.53 € 270.86
See Appendix for detail description and sources for drug, adminis-
tration, and supply cost by country
Table 3 Utilities for patients with and without SREs
Reduction in Utility
due to SRE*
Implied
Utility
Baseline (no SRE) NA 0.76
Pathological vertebral
fractures
20% in 34% of patients
with symptomatic fractures
0.7083

Pathological non-vertebral
fractures
20% 0.608
Spinal cord compression 80% 0.152
Radiation therapy 40% 0.304
Surgery to the bone 60% 0.456
* Source adapted from Hillner et al. [18]
 i.e., 34% 9 0.76 9 (1–20%) ? (1–34%) 9 0.76
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123Multivariate sensitivity analysis was addressed by a
combination of bootstrapping and probabilistic sensitivity
analysis (PSA). The uncertainty from the trial data is
captured by the bootstrap procedure and the uncertainty
from the model is addressed by the PSA. The latter is a
form of sensitivity analysis whereby the model parameters
are replaced by random draws from the probability distri-
butions that reﬂect the uncertainty of these parameters. For
each combination of random draws, new outcomes are
generated. When this process is repeated many (e.g., 1,000)
times, one may picture the outcomes as distributions (given
1,000 observations). Bootstrapping is also a type of
uncertainty analysis. This means that one simulates a large
number of new trials (e.g. 1,000) of the same size by
drawing—with replacement—from the original trial. Each
new trial leads to new outcomes and as with the PSA, one
may describe the results using distributions. Here, both
approaches are carried out simultaneously, meaning that
each combined random drawn from the PSA is linked to a
newly simulated trial. As such, uncertainty from trial
results and from model parameters is simultaneously
assessed. The results of the joint 1,000 PSA and bootstrap
replicates can then be analyzed and described using simple
descriptive statistics.
Speciﬁcally, one may estimate the proportion of the
1,000 model replications in which ZOL is cost savings or
cost-effective at a given k (e.g., € 30,000). Acceptability
curves [20] can be drawn showing the proportion of model
replications in which ZOL is cost-effective versus placebo
for increasing levels of k, providing an indication of the
level of uncertainty associated with the results. In the
present analysis, 1,000 iterations of the model were gen-
erated, using a random selection of values according to the
parametric uncertainty distributions speciﬁed in Table 4.
Following widely used country-speciﬁc health technol-
ogy assessment guidelines, all costs and beneﬁts for eco-
nomic and clinical outcomes occurring beyond the ﬁrst
year of the analysis were discounted at the rate of 5% per
annum in France and Germany, and 3.5% in the UK. All
costs were expressed in 2008 prices. For the purpose of
comparison across countries, all costs in Great Britain
pounds were converted into Euro currency at the rate of
£1 = € 1.1196 (as of Dec 12, 2008).
Results
Base case economic results
The use of ZOL was associated with an estimated average
of 0.67 SREs per person compared to 1.74 SREs per person
in patients receiving placebo, for an average reduction of
1.07 SREs per patient (Table 5). The use of ZOL in France
and Germany was associated with an estimated average of
0.6638 discounted QALYs compared to 0.5075 discounted
QALYs in patients receiving placebo (Table 5). These
Table 4 Summary of model input parameters for sensitivity analyses
Baseline Low
a High
a Assumed distribution
a
Baseline utility
b 0.76 0.52 1.00 Uniform
Reduction in utility due to pathological vertebral fractures
b 20% 0% 40% Uniform
Reduction in utility due to pathological non-vertebral fractures
b 20% 0% 40% Uniform
Reduction in utility due to spinal cord compression
b 80% 60% 100% Uniform
Reduction in utility due to radiation therapy
b 40% 20% 60% Uniform
Reduction in utility due to surgery to the bone
b 60% 40% 80% Uniform
Proportion of vertebral fractures that are symptomatic
b 34% 17% 51% Uniform
Cost SREs
c, b –
d 0.5 9 baseline 1.5 9 baseline Uniform
Cost of labor for infusion
b –
e 0.5 9 baseline 1.5 9 baseline Uniform
Cost of material supplies for infusion
b –
e 0.5 9 baseline 1.5 9 baseline Uniform
Discount rate (France and Germany) 5% 0% 10% Not applicable
f
Discount rate (United Kingdom) 3.5% 0% 10% Not applicable
f
NA not applicable
a For assumed normal distributions, the low and high values represent the 5 and 95% conﬁdence interval limit, respectively; for assumed
uniform distributions, the low and high values represent the minimum and maximum value, respectively
b Same assumptions across all countries
c Same assumptions across all SREs
d Actual value varies from country to country (see text and Fig. 2 for details)
e Actual value varies from country to country (see text and Table 2 for details)
f Not included in multivariate sensitivity analysis
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different discounting rate. Therefore, treatment with ZOL
improved QALYs by 0.1563 in France and Germany and
by 0.1575 in the UK (Table 5).
Compared to placebo, the use of ZOL was associated
with a reduction in SRE-related discounted costs (-€ 4,196
in France, -€ 3,880 in Germany, and -€ 3,355 in the UK)
(Table 5). With the addition of the drug and administration
costs of ZOL (?€ 2,837 in France, ?€ 2,657 in Germany,
and ?€ 2,636 in the UK), the net costs in the ZOL arm
(Table 5) were € 1,358, € 1,223, and € 719 less than in
the placebo group, in France, Germany, and the UK,
respectively.
Overall, the use of ZOL appears to be associated with
net savings in QALY and reduction in costs and is there-
fore superior to placebo Fig. 1.
Univariate sensitivity analysis
As indicated in Fig. 2, a few of the model inputs (other
than the results of the trial itself) individually affect the
conclusions of the analysis. Speciﬁcally, none of the
changes in the individual model parameter resulted in a
negative NMB (assuming a willingness to pay of € 30,000
per QALY gained). The most sensitive variables were the
assumptions regarding the utility of metastatic RCC with-
out SRE (which is used as the background utility), and the
cost of SREs (in particular the costs of non-vertebral
fractures and spinal cord compression). Changes in the
value of the other parameters typically have less impact on
the results.
Multivariate sensitivity analysis
The multivariate sensitivity analysis was conducted to
determine the impact of altering multiple variables
simultaneously. This analysis conﬁrmed that ZOL is
cost-effective. Figure 3 presents the acceptability curves
for the cost-effectiveness of ZOL versus placebo in the
three countries. ZOL was cost saving and improved
QALY in 67% of the 1,000 multivariate sensitivity
analysis simulations in the UK and 77% of the simula-
tions in France (with the proportion for Germany lying
in the range). The incremental cost per QALY gained
was below € 30,000 in approximately 93–94% of the
1,000 simulations.
Table 5 Base case QALY and
costs for ZOL and Placebo
groups
Placebo
(N = 19)
ZOL 4 mg
(N = 27)
Difference
France
SRE per person 1.74 0.67 -1.07
Discounted QALY per person 0.5075 0.6638 0.1563
Discounted SRE-related costs per person € 6,414 € 2,218 -€ 4,196
Discounted drug costs per person € 0 € 2,837 € 2,837
Discounted total costs per person € 6,414 € 5,056 -€ 1,358
Cost per QALY -€ 8,689
Net monetary beneﬁt € 6,049
Germany
SRE per person 1.74 0.67 -1.07
Discounted QALY per person 0.5075 0.6638 0.1563
Discounted SRE-related costs per person € 6,347 € 2,468 -€ 3,880
Discounted drug costs per person € 0 € 2,657 € 2,657
Discounted total costs per person € 6,347 € 5,125 -€ 1,223
Cost per QALY -€ 7,820
Net monetary beneﬁt € 5,913
United Kingdom
SRE per person 1.74 0.67 -1.07
Discounted QALY per person 0.5086 0.6661 0.1575
Discounted SRE-related costs per person € 4,798 € 1,443 -€ 3,355
Discounted drug costs per person € 0 € 2,636 € 2,636
Discounted total costs per person € 4,798 € 4,079 -€ 719
Cost per QALY -€ 4,566
Net monetary beneﬁt € 5,444
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The results of the present analysis suggest that the use of
ZOL in patients with RCC and bone metastases is highly
cost-effective from a government payer perspective in
France, Germany, and the UK. ZOL reduced the health
care costs associated with SREs by € 3,355 per patient in
the UK to € 4,196 per patient in the France (with Germany
in between with cost reductions of € 3,880). Even after
accounting for the drug and administration costs, ZOL
remained cost saving (ranging from € 719–€ 1,358 per
patient, depending on the country). Since ZOL is also
predicted to improve quality of life due to the reduction in
the frequency of SREs and longer survival, ZOL is eco-
nomically preferred to no therapy (i.e., placebo). These
results were found to be robust to variations in input
parameter values. In the PSA, the incremental cost per
QALY gained was € 30,000 or less in 93–94% of the 1,000
simulations, indicating at the same time that in 6–7% of
model iterations ZOL is cost ineffective.
The results also indicate that the cost-effectiveness is
relatively comparable across the three countries of interest,
despite the differences in costing methodologies and
assumptions.
The main strength of this analysis is the direct reliance
on the patient-level data regarding SREs and survival to
estimate the costs and quality of life impacts of these
events and the beneﬁts of therapy with ZOL. The reliance
on the patient-level data allows a more comprehensive
assessment of the uncertainty around the point estimate of
cost-effectiveness than those presented in previous cost-
effectiveness analyses of bisphoshonates [18, 21–24].
The analysis includes several important limitations.
First, the results are based on a post hoc, retrospective
analysis of a very small subgroup of patients with RCC
who were taken from a larger pool of patients with bone
metastases secondary to solid tumors other than breast or
prostate cancer who were enrolled in a randomized clinical
trial of ZOL versus placebo. Therefore, the present analysis
must be considered exploratory and should be replicated in
a larger, pre-planned study designed to formally test the
hypothesis that ZOL is effective and cost-effective in a
comparable population of RCC patients with bone
metastases.
Another important limitation of the analysis is the very
small sample size of patients on which it is based. Only
19 placebo and 27 ZOL patients were included, limiting
the generalizability and power of the analysis. Neverthe-
less, this limited evidence was the only peer-reviewed,
published [10] information at our disposal regarding the
effect of ZOL in RCC patients with bone metastasis. To
address the uncertainty associated with this limitation,
multivariate sensitivity analysis using a combination of
probabilistic sensitivity analysis and bootstrapping was
used. The results of these analyses provide some cautious
reassurance in that ZOL was cost saving and improved
QALY in 67% of the 1,000 multivariate sensitivity
analysis simulations in the UK and 77% of the simula-
tions in France (with the proportion for Germany
approximately 75%). The incremental cost per QALY
gained was below € 30,000 in approximately 93–94% of
the 1,000 simulations. In this context, the use of boot-
strapping to estimate the level of uncertainty surrounding
the estimate of cost-effectiveness is of limited value as
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France € 373  € 5,326 € 1,791 € 5,326 € 9,818
Germany € 144 € 4,215 € 3,000 € 5,223 € 8,446
UK € 189 € 6,158 € 468 € 3,346 € 5,060
Vertebral fractures Nonvertebral fractures Radiation therapy to bone Surgery to bone Spinal cord compression
Fig. 1 Costs of SRE by SRE
type and country see Appendix
for detail description and
sources of SRE cost by country
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123the re-sampling is based on the same small number of
patients. As such, there is no question again that the
results of this analysis should be replicated in a larger
group of patients.
Despite the above limitation, it may be important to
place the present results pertaining to this small subgroup
of RCC patients in the broader context of the effectiveness
(and cost-effectiveness) of ZOL in other solid tumors. This
agent has been shown to be effective compared to placebo
in patients with bone metastases secondary to breast cancer
[25], prostate cancer [26], and other solid tumors [9].
Economic studies adopting a European perspective have
also shown that ZOL is cost-effective (i.e., cost per
QALY\€ 30,000) in prostate cancer [12], breast cancer
[11], lung cancer [13], and other solid tumors [27]. Thus,
even though the sample size upon which this analysis is
based is small, its results are consistent with the broader
evidence pertaining to ZOL in solid tumors.
The costs and quality-adjusted survival of the patients
included in the analysis were not directly observed during
the trial. Accordingly, these were estimated on the basis of
the observed frequency and types of SREs combined with
information collected outside of the trial, such as DRG
payments. A key issue is whether the estimates of costs
from DRG systems, which are typically assumed to rep-
resent averages across many patient groups, apply to RCC
cancer patients. For instance, compared to patients without
cancer and bone metastases, patients with bone metastases
may experience far more complicated recoveries from
(long-bone) fractures than other patients, as bone remod-
eling following a fracture may be severely compromised
due to increased osteoclast and reduced osteoblast activity
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Fig. 2 Univariate Sensitivity Analysis around the NMB of Zometa
versus Placebo Legend: This ﬁgure presents the results of the
univariate sensitivity analysis on the NMB (assuming a k = € 30,000)
of ZOL versus placebo using tornado diagrams in the three countries
of interest. The model parameters with the largest inﬂuence on the
NMB (i.e., for which the change in parameter value is associated with
the larges change in NMR) is placed at the top of the tornados. Other
variables are placed in decreasing order of inﬂuence. The vertical
lines at the center of the tornadoes represent the point estimates of the
NMB (€ 6,049 in France, € 5,913 in Germany, and € 5,444 in the
UK). None of the changes in the value of the parameters resulted in
the NMB to be less than € 0, implying that none of these changes
resulted in the Cost per QALY to be higher than € 30,000 (=k)
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123[28]. In addition, the cost estimates used in this analysis
may be underestimated because outpatient costs were lar-
gely ignored. It is likely that a more protracted recovery
from complicated SREs such as non-vertebral fracture or
bone surgery will require signiﬁcant outpatient care. It is
likely that the exclusion of outpatient care costs contribute
to important underestimations of SRE-related costs.
Likewise, preference scores for the time spent with
RCC, with or without SREs, were constructed on the basis
of the literature. A search of the Medline-indexed literature
identiﬁed only one reference that could be used to directly
estimate the base case utility of metastatic RCC [17]. As
the results of the univariate sensitivity analysis showed, the
background utility of patients with RCC and bone metas-
tases (but without concurrent SRE) is an important driver
of cost-effectiveness. This is because the utility of time
associated with an SRE was estimated using a multiplica-
tive model, in which the background utility level is mul-
tiplied by utility decrements adapted from those ﬁrst
initially proposed by Hillner et al. [18]. Therefore, the
lower the assumed background utility level, the lower the
gain in utility achievable from preventing a given SRE.
The present analysis included the point estimate differ-
ence in survival between the placebo and treatment groups
in the calculated QALY saved. However, this inclusion of
the survival difference may arguably be biased in favor of
ZOL since this difference was not statistically signiﬁcant,
as reported in Lipton et al. [10]. More broadly speaking, a
debate exists as to whether it is methodologically appro-
priate to include survival gains in economic analyses when
these are not statistically signiﬁcant [29–33]. However, the
question addressed by the economic analysis is much
broader: it seeks to understand whether a treatment is cost-
effective when considering all costs and beneﬁts—not just
survival—and includes the uncertainty surrounding these
costs and beneﬁts. Ignoring some of these effects on the
basis that they are statistically insigniﬁcant does not
address whether they are clinically—or more broadly,
economically important. For instance, ignoring the differ-
ence in survival would have resulted in a reduction in the
estimate of QALY gained, from 0.131 to 0.018. However,
if survival between placebo and treatment were to be
assumed to be identical (i.e., the difference in survival is
ignored), then the estimated cost of SREs and drug also
must be proportionately modiﬁed to reﬂect the adjusted
survival, which determine the level of exposure to the SRE
risk and the need for additional infusion with ZOL. Spe-
ciﬁcally, the SRE and drug costs in the treatment group
would have to be reduced (if it is assumed that the treat-
ment group’s survival is exaggerated) or the cost of SRE in
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Fig. 3 Acceptability Curve for the Cost-Effectiveness of ZOL
Legend: The acceptability curve shows the probability that ZOL is
cost-effective compared to placebo, given the results of the 1,000
PSA simulations, across a range of maximum monetary values that
decision makers might be willing to pay for a QALY saved (along the
‘‘x’’ axis). For instance, if decision makers are not willing to pay
anything for a QALY saved (i.e., they demand that ZOL is cost
saving, regardless of the impact on QALYs), then approximately 67%
(for the UK) to 77% (for France) of the 1,000 model runs in PSA met
this requirement (the acceptability curve crosses the Y axis at the 67%
to 77% mark). As the willing to pay for a QALY saved increases, the
proportion of 1,000 simulations that meet the decision makers’
criteria also increases, to reach a maximum of 94% for France and
Germany around € 22,000 and 93% for the UK around € 34,000
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123the placebo group would have to be increased (if it is
assumed that the placebo group’s survival is underesti-
mated). These cost adjustments would likely offset the
reduction in QALY gained in the cost-effectiveness ratio.
On the other hand, due to the lack of data, the analysis also
excluded non-SRE cost, such as the costs of routine or
palliative care, incurred by patients in both the placebo and
treatment groups. Since patients in the ZOL group were
assumed to live longer, it is likely that these patients also
incurred higher non-SRE-related care costs. Therefore,
instead of arbitrarily omitting possible effects of ZOL and
trying to adjust the results to account for this omission, the
present analysis included as much of the evidence at our
disposal, including the degree of uncertainty surrounding
this evidence.
ZOL is the only bisphosphonate speciﬁcally approved
for the management of SREs in solid tumors other than
breast cancer. In addition, no clinical trials have reported
on the efﬁcacy of other bisphosphonates for the manage-
ment of bone metastases in patients with RCC. It would be
inappropriate to assume that all bisphosphonates are
equally effective. For instance, ZOL has been shown to be
more effective than pamidronate for the prevention of
SREs in patients with bone metastases subsequent to breast
cancer [34]. While ZOL has been shown to be effective in
preventing SREs in patients with bone metastases sec-
ondary from prostate cancer [35], a trial of pamidronate did
not demonstrate comparable effects [36].
The clinical trial upon which the present analysis was
based was initiated in early 2000. Since that time, the
management of RCC has changed dramatically with the
introduction of newer agents such as tyrosine kinase
inhibitors [37]. These newer agents are associated with
higher response rate, longer (progression-free) survival,
and improved quality of life. Thus, it is unclear whether the
unique economic value of ZOL therapy as estimated in the
present analysis, reﬂecting the era of interferon therapy,
will remain the same in patients treated with the newer
agents.
Conclusions
The results of a retrospective subgroup analysis of patients
with RCC and bone metastases have demonstrated that
signiﬁcant clinical beneﬁts can be expected from ZOL
therapy [10]. The results of the present analysis also sug-
gest that ZOL is likely economically attractive and is
predicted to lead to cost savings or to be very cost-effec-
tive. These results, based on a post hoc, retrospective
analysis of a small sample of RCC patients from a larger
trial of solid tumor patients, should be further conﬁrmed in
pre-planned analyses of larger, prospective trials.
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Appendix
See Tables 6, 7, 8, 9, 10, 11.
Table 6 Cost of SREs in France
SRE Base Description/source
Vertebral fractures € 373 Average of DRGs 08M11 V
a and 08M11 W
b multiplied by hospitalization
rate [14]
Non-vertebral fractures € 5,326 Average of DRGs 08M11 V
a and 08M11 W
b
Radiation therapy to bone € 1,791 Average of inpatient and outpatient radiation therapy. Inpatient estimate
taken from DRG 17K06Z
c (€ 2,843.5); Outpatient cost (€ 1,700) taken
from Durand-Zaleski [38]; Frequency of inpatient (8%) v. outpatient (92%)
radiation taken from Groot et al. [39]
Surgery to bone € 5,326 Average of DRGs 08M11 V
a and 08M11 W
b
Spinal cord compression € 9,818 DRG 01C05 W
d
DRG diagnosis-related group
a Pathologic fractures and malignant problems of the musculoskeleton and connective tissue without CMA
b Pathologic fractures and malignant problems of the musculoskeleton and connective tissue with CMA
c Other radiotherapies and internal-source irradiations
d Interventions on the spine and marrow for neurologic problems with CMA
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123Table 7 Cost of SREs in Germany
SRE Base Description/source
Vertebral fractures € 144 DRG I65C
a multiplied by hospitalization rate [14]
Non-vertebral fractures € 4,215 DRG I13B
b
Radiation therapy to bone € 3,000 DRG I54Z
c
Surgery to bone € 5,223 Average of DRG I13A
d and DRG I13B
b
Spinal cord compression € 8,446 DRG B03X
e
a Malign neoplasia of connective tissue including pathological fracture, age[16 years, without extremely severe concurrent diseases
(€ 2,053.82)
b Complex surgery of the humerus, tibia, ﬁbula or ankle, without several surgeries, without two-sided surgeries, without complex procedure,
without complex diagnosis (€ 4,214.70)
c Radiotherapy of diseases or malfunction of the musculo-skeletal system and connective tissue, less than 9 cycles
d Complex surgery of the humerus, tibia, ﬁbula or ankle, with several surgeries, two-sided surgeries, complex procedure or complex diagnosis
(€ 6,231.89)
e Surgery of non-acute para-/tetraplegia or surgery of the spine or spinal cord when there exist malign neoplasias or when there exist (extremely)
severe concurrent diseases or surgery due to cerebral paralysis, muscular dystrophy, neuropathy with severe concurrent diseases
Table 8 Cost of SREs in the UK
SRE Base Description/source
Vertebral fractures € 189 Average of HRG code HD36C, HD36B, HD36A
a weighted by the number of
treatment in each HRG. NHS National Schedule of Reference Costs 2006–07,
£2,405, multiplied by hospitalization rate [14]
Non-vertebral fractures € 6,158 Average of HRG code HD36C, HD36B, HD36A
a weighted by the number of
treatment in each HRG. NHS National Schedule of Reference Costs 2006–07,
£2,405, plus the estimated cost of outpatient care for long-bone fractures for
3 months (£5,073) assumed to be incurred by 61% of patients with non-vertebral
fractures (total of £5,073 9 61% = £3,095) (based on Ross et al. [24] set of
assumptions)
Radiation therapy to bone € 468 Average of HRG code SC21Z, SC22Z, SC23Z, SC24Z, SC25Z, SC26Z, SC27Z,
SC28Z,
b weighted by the number of treatment in each HRG. NHS National
Schedule of Reference Costs 2006–07 http://www.dh.gov.uk/en/
Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/
DH_082571?IdcService=GET_FILE&dID=159075&Rendition=Web
Assumes as Ross et al. [24] that 3 sessions take place. Includes the cost of cost
of a visit (code 360 Genito-Urinary Medicine contact at £145), the total cost
would be £467.53
Surgery to bone € 3,346 HRG HD36A–Pathological Fractures or Malignancy of Bone and Connective Tissue
with Major CC. NHS National Schedule of Reference Costs 2006–07
Spinal cord compression € 5,060 HRG HC25A–Non-Traumatic Spinal Cord Disorders with Major CC. NHS National
Schedule of Reference Costs 2006–07
a HRG Labels: HD36C—Pathological Fractures or Malignancy of Bone and Connective Tissue without CC; HD36B—Pathological Fractures or
Malignancy of Bone and Connective Tissue with CC; HD36A—Pathological Fractures or Malignancy of Bone and Connective Tissue with
Major CC
b HRG Labels: SC21Z—Deliver a fraction of treatment on a superﬁcial or orthovoltage machine; SC22Z—Deliver a fraction of treatment on a
megavoltage machine; SC23Z—Deliver a fraction of complex treatment on a megavoltage machine; SC24Z—Deliver a fraction of radiotherapy
on a megavoltage machine using general anesthetic; SC25Z—Deliver a fraction of Total Body Irradiation; SC26Z—Deliver a fraction of
intracavitary radiotherapy without general anesthetic; SC27Z—Deliver a fraction of intracavitary radiotherapy with general anesthetic; SC28Z—
Deliver a fraction of interstitial radiotherapy
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123Table 9 Cost of drug and drug administration in France
France Units* Cost/unit Sources for cost/unit Cost
Drug cost 1.00 € 270 Novartis data on ﬁle (IMS price) (Oct 28th 2008) € 270.00
Labor costs (in minutes) € 18.72
Physician time 11.12 € 0.62 Annual salary 61620.22 per year
http://www.legifrance.gouv.fr/jopdf//jopdf/2008/0329/
joe_20080329_0008.pdf
€ 6.86
Pharmacy technician time 10.58 € 0.21 http://www.wk-pharma.fr/annonces/
static.php?template=grille_salaires.html&deplies=6&selectionnes=6
€ 2.27
Nurse time 44.25 € 0.22 Gross hourly rate of nurse (13 Euros)
http://www.syndicat inﬁrmier.com/article.php3?id_article = 503&
var_recherche = heures
€ 9.59
Supplies € 3.36
Needle 2.00 € 0.19 0,5 cc 50U/ml http://www.lavitrinemedicale.com/
pages/affProd.asp?idProduit=1478
€ 0.37
Gauze 2.00 € 0.02 Compresses de gaze non-steriles 17 ﬁls, 8 plis. 5 9 7,5 cm
http://www.lavitrinemedicale.com/
pages/affProd.asp?idProduit=1367
€ 0.04
Alcohol swab 2.00 € 0.04 Tampons alcoolises http://www.lavitrinemedicale.com/
pages/affProd.asp?idProduit=1472
€ 0.07
Syringe 2.00 € 0.09 10 cc Source: http://www.lavitrinemedicale.com/
pages/affProd.asp?idProduit=1520
€ 0.18
Set of gloves 3.00 € 0.13 Gants micro-touch hydracare http://www.lavitrinemedicale.com/
pages/affProd.asp?idProduit=1247
€ 0.39
Medical tape 1.00 € 0.02 Bandes de gaze 4 m 9 5c mhttp://www.lavitrinemedicale.com/
pages/affProd.asp?idProduit=1345
€ 0.02
Sample tubes 2.00 € 0.16 Tube sous vide en verre venoject terumo 3 ml serum 65 9 10,25 mm
http://www.socimed.com/tube-sous-vide-
verre-venoject-terumo-serum-1025mm-p-2904.html
€ 0.32
Disposable i.v. set 1.00 € 1.94 http://www.socimed.com/catheter-intraveineux-
surﬂo-terumo-p-3087.html
€ 1.94
Thermometer cover 1.00 € 0.04 Lubriﬁee, les 100; http://www.lavitrinemedicale.com/
pages/affProd.asp?idProduit=380
€ 0.04
Grand total € 292.08
* Based on a micro-costing study of DesHarnais-Castel et al. [16]
Table 10 Cost of drug and drug administration in Germany
Germany Units* Cost/unit Sources for cost/unit Cost
Drug cost 1.00 € 254 Novartis data on ﬁle (IMS price) (Oct 28th 2008) € 254.00
Labor costs (in minutes) € 17.80
Physician time 11.12 € 0.42 General physician salary, International Labour Organization.
LABORSTAT. http://laborsta.ilo.org/cgi-bin/brokerv8.exe
€ 4.64
Pharmacy technician time 10.58 € 0.22 Auxiliary nurse salary, International Labour Organization.
LABORSTAT. http://laborsta.ilo.org/cgi-bin/brokerv8.exe
€ 2.28
Nurse time 44.25 € 0.25 Professional nurse salary, International Labour Organization.
LABORSTAT. http://laborsta.ilo.org/cgi-bin/brokerv8.exe
€ 10.88
Supplies € 1.72
Needle 2.00 € 0.03 Normkanu ¨len http://www.medicotec-shop.de/?p=artdetails&from_
page=artliste&Artikel=52354&suchtext=&form_sortBy=
€ 0.06
Gauze 2.00 € 0.02 Gazin-Kompressen steril groß, 10 9 10 cm (5 9 2); 56 Pack
http://www.megro.de/top/is.top
€ 0.03
Alcohol swab 2.00 € 0.03 http://www.dammeyer-selzer.de/sonderangebote/index.htm € 0.06
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